A recent meta-analysis of 6 randomised phase II and III studies looked at complete response rates to immune checkpoint inhibitors in patients with renal cell carcinoma.

Data from the following 6 studies were analysed; CheckMate 214, CheckMate 025, KEYNOTE-426, Javelin Renal 101, IMmotion150, and IMmotion151, which included a total of 4531 patients. The incidence of complete response in the patients taking immune checkpoint inhibitors was 6.2% versus 2.6% in the control patients.

In conclusion, treatment with immune checkpoint inhibitors results in higher complete response rates in patients with advanced RCC.

Read more in Practice Update here